DOCSLIB.ORG

EMCDDA Cannabis Reader

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EMCDDA Cannabis Reader ISSN 1606-1691 A cannabis reader: global issues and local experiences 05 06 15 TD-32-07-001-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The Centre’s publications are a prime source of information for a wide range of audiences including policy-makers and their advisers; professionals and researchers working in the drugs field; and, more broadly, the media and general public. EMCDDA monographs are comprehensive scientific publications containing thematic papers prepared in the context of the Centre’s activities. Topics cover a wide range of issues relating to science, policy, epidemiology and best EMCDDA practice. MONOGRAPHS A cannabis reader: global issues and local experiences Price (excluding VAT) in Luxembourg: EUR 20 per volume MONOGRAPHS EMCDDA VOL. I VOL. 8 8 I VOLUME EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 I VOLUME Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document. The contents of this publication do not necessarily reflect the official opinions of the EMCDDA's partners, any EU Member State or any agency or institution of the European Union or European Communities. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu). Europe Direct is a service to help you find answers to your questions about the European Union Freephone number: 00 800 6 7 8 9 10 11 This publication should be referenced as: EMCDDA (2008), A cannabis reader: global issues and local experiences, Monograph series 8, Volume 1, European Monitoring Centre for Drugs and Drug Addiction, Lisbon. References to chapters in this monograph should include, where relevant, references to the authors of each chapter, together with a reference to the wider publication. For example: Corrigan, D. (2008), ‘The pharmacology of cannabis: issues for understanding its use’, in: A cannabis reader: global issues and local experiences, Monograph series 8, Volume 1, European Monitoring Centre for Drugs and Drug Addiction, Lisbon. The publication is available on the Internet at: http://www.emcdda.europa.eu/publications/monographs/cannabis Cataloguing data can be found at the end of this publication. Luxembourg: Office for Official Publications of the European Communities, 2008 ISBN 978-92-9168-311-6 © European Monitoring Centre for Drugs and Drug Addiction, 2008 Reproduction is authorised provided the source is acknowledged. Printed in Belgium Rua da Cruz de Santa Apolónia 23–25, P-1149-045 Lisbon Tel. (351) 21 811 30 00 • Fax (351) 21 813 17 11 [email protected] • http://www.emcdda.europa.eu Contents Introduction ix Foreword xiii Wolfgang Götz Overview of Volume 1 xvii Sharon Rödner Sznitman and Börje Olsson Part I: Cannabis in the past Chapter 1: Cannabis as medicine in Europe in the 19th century 3 Manfred Fankhauser Chapter 2: The re-emergence of the therapeutic use of cannabis products: recent developments and future prospects 17 John Witton Chapter 3: The pharmacology of cannabis: issues for understanding its use 27 Desmond Corrigan Chapter 4: Soma, the Wootton Report and cannabis law reform in Britain during the 1960s and 1970s 39 Stephen Abrams Chapter 5: Cannabis’s role in drawing attention to ‘the drugs problem’ in Sweden 51 Börje Olsson Chapter 6: Enlargement 2005: cannabis in the new EU Member States 63 Jacek Moskalewicz, Airi-Alina Allaste, Zsolt Demetrovics, Danica Klempova and Janusz Sierosławski, with Ladislav Csemy, Vito Flaker, Neoklis Georgiades, Anna Girard, Vera Grebenc, Ernestas Jasaitis, Ines Kvaternik Jenko, Richard Muscat, Marcis Trapencieris, Sharon Vella and Alenka Žagar v Contents Part II: Policies, legislation and control strategies Chapter 7: Cannabis control in Europe 97 Danilo Ballotta, Henri Bergeron and Brendan Hughes Chapter 8: In thinking about cannabis policy, what can be learned from alcohol and tobacco? 119 Robin Room Chapter 9: An open front door: the coffee shop phenomenon in the Netherlands 137 Dirk Korf Chapter 10: Cannabis policy: tightening the ties in Denmark 157 Vibeke Asmussen Chapter 11: Cannabis: a harm reduction perspective 171 Andrew Bennett Part III: Supply and production issues Chapter 12: Global cannabis cultivation and trafficking 187 Ted Leggett and Thomas Pietschmann Chapter 13: Monitoring cannabis availability in Europe: issues, trends and challenges 215 Chloé Carpentier, Meredith Meacham and Paul Griffiths Chapter 14: Understanding cannabis potency and monitoring cannabis products in Europe 239 Leslie King Chapter 15: Multinational export–import ventures: Moroccan hashish into Europe through Spain 261 Juan Francisco Gamella and Maria Luisa Jiménez Rodrigo Chapter 16: An analysis of the significance of supply and market factors for variations in European cannabis use 291 Leif Lenke Appendix: Grey literature list 300 Index 311 vi Introduction Smoked, eaten, imbibed — or just talked about — it seems the world has a strong appetite for cannabis. An estimated one in five European adults have tried it. Thirteen million Europeans have consumed it in the past month. Globally, nearly 50 000 tonnes of cannabis herb or resin is produced for consumption each year. Little wonder, then, that cannabis has become a controversial cultural and commercial phenomenon. Today, cannabis has a unique ability to divide opinion among policymakers, scientists, law enforcers, drugs professionals and consumers. This EMCDDA cannabis monograph addresses one basic question. How can I find quality information on cannabis, amid all the bias and opinion? During the editing of this monograph it soon became clear that the EMCDDA was entering an area crowded with general guides, even competing cannabis monographs. This is where the idea of a cannabis ‘reader’ emerged. Our audience — researchers, parliamentarians, drugs professionals, students, European citizens — is currently faced with an overload of professional publications. Added to this is the daily flood of information on the Internet, often crusading in nature, and sometimes misleading. This threatens to obscure the genuine progress made in cannabis research during the past two decades. The EMCDDA cannabis reader underlines the point that cannabis is not just a static, unchanging plant, but a dynamic product that is subject to gradual evolution in potency, prevalence, cultivation, legislative and public health concerns. In this monograph, leading experts provide short, sharp insights on a range of cannabis topics while offering advice on further reading for each topic. Brief editorial notes provide concise introductions to each topic, occasionally drawing attention to political sensitivities and the need for a ‘critical eye’. So this cannabis reader has a value, both as a shortcut to researchers entering the area and a synthesis for experts. You will find a wide range of views expressed in the chapters in this monograph, not all of them in agreement. The arguments, tone and conclusion of each chapter is the responsibility of the author alone, and is not necessarily endorsed or supported by the EMCDDA. This reflects the wider discourse on cannabis where different positions and perspectives often lead to different conclusions being drawn from the same evidence. We believe each chapter represents a useful contribution to the overall debate, even if their individual perspectives differ. ix Introduction Two volumes, multiple audiences: policymakers, enforcers, researchers, professionals The monograph is divided into two volumes, each comprising three sections. There are a number of reasons for the two-volume approach. While complementary, each has a slightly different audience. The first volume centres on political, legislative, commercial and social developments relating to cannabis. Its core audience thus comprises policymakers, sociologists, historians, journalists and those involved in enforcement. The second volume is very much centred on drugs professionals working in the fields of treatment, prevention and healthcare. Volume 1 • Cannabis in the past • Policies, legislation and control strategies • Supply and production issues Volume 2 • Epidemiology • Health effects of cannabis use • Prevention and treatment Changing perspectives: from global issues to local experiences What unites both volumes is an attempt to fuse general chapters with specific case studies. Within each section, you will encounter a progression from a ‘top level’ to a ‘close-up’ view of the subject. So each section begins with chapters providing a general introduction to a single cannabis issue, often of an encyclopaedic nature, together with a summary of the current state of scientific research. The monograph then ‘zooms in’ with a case study about a specific aspect of cannabis. In
Load more

Recommended publications
  • Report of the International Narcotics Control Board for 2008
    E/INCB/2008/1 preparations containing pseudoephedrine were reported 536. The unsafe practice of sharing needles among in Peru. In July 2008, the Argentine authorities drug abusers remains one of the main causes of HIV identified a case involving the diversion of ephedrine transmission in many countries in South-East Asia. The on a large scale and destroyed a methamphetamine Australian Agency for International Development laboratory in their country. The Board requests the launched the HIV/AIDS Asia Regional Program in Governments of all countries in South America to Chiang Mai, Thailand, in April 2008, to help stop the continue monitoring the licit trade in precursors of spread of HIV/AIDS in South-East Asia through amphetamine-type stimulants, including ephedrine and advocacy, knowledge-sharing and strategic pseudoephedrine traded as raw material or in the form partnerships. The Program, which is expected to last of pharmaceutical preparations, in order to prevent the eight years, involves Governments, regional agencies, diversion of those precursors from licit channels. civil society organizations and drug abuse prevention networks in controlling the spread of HIV transmission associated with drug abuse in Cambodia, China, the C. Asia Lao People’s Democratic Republic, Myanmar, the Philippines and Viet Nam. East and South-East Asia 537. National authorities of countries in East and 1. Major developments South-East Asia continued to report significant seizures of drugs smuggled through the postal system. Large 534. The Board noted the large-scale smuggling of amounts of benzodiazepines and cannabis were seized, illicit drugs into East and South-East Asia from outside but the most often seized drug was methamphetamine.
    [Show full text]
  • Prohibition, American Cultural Expansion, and the New Hegemony in the 1920S: an Interpretation
    Prohibition, American Cultural Expansion, and the New Hegemony in the 1920s: An Interpretation IAN TYRRELL* In the [920s American prohibitionists, through the World League against Alcohol­ ism, sought to extend their war on liquor beyond the boundaries of the United States. Prohibitionistsfailed in their efforts due to anti-American sentiment, complex class and cultural opposition to prohibition, and negative reporting of the experi­ ment with prohibition in the U.S. Nevertheless, restrictive anti-alcohol laws were introduced in a number ofcountries. Moreover, the efforts ofAmerican prohibition­ ists furthered the larger process of American cultural expansion by emphasizing achievements of the U.S. in economic modernization and technical advancement. This episode in American cultural expansion occurred with the support of anti­ alcohol groups in foreign countries that embraced the message equating American reform with modernity. Prohibitionists abroad colluded in the process, thereby accepting a form ofAmerican cultural hegemony. En 1920, par l'intermédiaire de la World League against Alcoholism, les prohibi­ tionnistes américains se sont efforcés de pousser leur lutte contre l'alcool au-delà des frontières des États-Unis. Cependant, le sentiment anti-américain, l'opposition complexe des classes et de la culture à l'endroit de la prohibition ainsi que la mauvaise presse dont l'expérience américaine a fait l'objet ont fait échouer leurs efforts. Néanmoins, plusieurs pays ont adopté des lois restrictives contre l'alcool. Qui plus est, les efforts des prohibitionnistes américains ont favorisé l'expansion de la culture américaine en mettant en valeur les réussites des É.-u. au chapitre de la modernisation économique et de l'avancement de la technologie.
    [Show full text]
  • July 29, 2013 Alcohol Policy in Wisconsin History
    July 29, 2013 Alcohol Policy in Wisconsin History No single aspect of Wisconsin’s history, regulatory system or ethnic composition is responsible for our alcohol environment. Many statements about Wisconsin carry the implicit assumption that our destructive alcohol environment (sometimes called the alcohol culture) has always been present and like Wisconsin’s geographic features it is unchanging and unchangeable. This timeline offers an alternative picture of Wisconsin’s past. Today’s alcohol environment is very different from early Wisconsin where an active temperance movement existed before commercial brewing. Few people realize that many Wisconsin communities voted themselves “dry” before Prohibition. While some of those early policies are impractical and even quaint by modern standards, they suggest our current alcohol environment evolved over time. The policies and practices that unintentionally result in alcohol misuse are not historical treasures but simply ideas that may have outlived their usefulness. This timeline includes some historical events unrelated to Wisconsin to place state history within the larger context of American history. This document does not include significant events relating to alcohol production in Wisconsin. Beer production, as well as malt and yeast making were important aspects of Wisconsin’s, especially Milwaukee’s, history. But Northwestern Mutual Life Insurance, its late President, Edmund Fitzgerald, industrial giant Allis Chalmers, shipbuilding and the timber industry have all contributed to Wisconsin’s history. Adding only the brewing industry to this time-line would distort brewing’s importance to Wisconsin and diminishes the many contributions made by other industries. Alcohol Policy in Wisconsin History 1776: Benjamin Rush, a physician and signer of the Declaration of Independence, is considered America’s first temperance leader.
    [Show full text]
  • Studies on New Pharmacological Treatments for Alcohol Dependence - and the Importance of Objective Markers of Alcohol Consumption
    Studies on new pharmacological treatments for alcohol dependence - and the importance of objective markers of alcohol consumption Andrea de Bejczy 2016 Addiction Biology Unit Section of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology Sahlgrenska Academy at University of Gothenburg Sweden Cover illustration: by A. de Bejczy Inspired by Stan Lee’s “The Invincible Ironman. The empty shell”, Marvel Comics “…HIS VOICE IS HOARSE, HIS HAND TREMBLING AS HE REACHES FOR THE GLEAMING OBJECT THAT SEEMS BOTH WONDERFUL AND TERRIBLE TO HIM…” Studies on new pharmacological treatments for alcohol dependence ©Andrea de Bejczy [email protected] ISBN: 978-91-628-9788-8 (printed publication) ISBN: 978-91-628-9789-5 (e-publication) http://hdl.handle.net/2077/42349 Printed in Gothenburg, Sweden 2016 By INEKO ii La familia iii iv Studies on new pharmacological treatments for alcohol dependence - and the importance of objective markers of alcohol consumption Andrea de Bejczy Addiction Biology Unit Section of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology Sahlgrenska Academy at University of Gothenburg ABSTRACT This thesis will guide you through three randomized controlled trials (RCT) on three pharmacotherapies for alcohol dependence; the antidepressant drug mirtazapine, the smoking cessation drug varenicline and the glycine-uptake inhibitor Org 25935. The mirtazapine study was an investigator initiated single- center harm-reduction study with alcohol consumption measured by self-report in a diary as main outcome. The results indicated that mirtazapine reduced alcohol consumption in males with heredity for alcohol use disorder (AUD). The Org 25935 study was an international multi-center study with abstinence as treatment goal, main time to relapse and alcohol consumption was measured by self-report collected by the Time Line Follow Back method (TLFB).
    [Show full text]
  • Contestation in Transition
    Contestation in transition Value-conflicts and the organization of markets - the cases of alcohol, gambling and coal Susanna Alexius, Daniel Castillo and Martin Rosenström, Score, November 2011 Abstract In this paper an historical comparative approach is applied to analyze how value conflict discourse and organization have evolved from the 1800s onward in three contested commodity markets – the alcohol, gambling and coal market. Situated mainly in the Swedish context, the three case studies demonstrate that the values at stake as well as the organizational arrangements brought forth in response to underlying value conflicts have changed significantly over time in all three markets. The commodities have stayed contested but for more or different reasons. Analyzing a dozen transformative moments in total we conclude that it matters to the organization of a market if there is an underlying value conflict and how this value conflict is configured. The comparative analysis sheds light on four processes in which value-conflict underpinnings of contested commodity markets may be shaped and altered: value addition, value expansion, value accumulation and value relocation. 2 Introduction ”Swedish regulation and public policy has for numerous decades been directed to general restrictive measures- high levels of alcohol taxation, low degree of accessibility and limited room for private profit seeking- thereby keeping down the consumption of alcohol, and consequently its harms.” SOU 2005:25, s. 37. “The particular character of games implies that gambling may be subjected to criminality. Gambling may cause economical and social problems for individuals as well as for society at large. Furthermore, gambling may cause health problems” SOU 2008:124 “The human impact on the climate by emission of so called greenhouse gases [primarily CO2] is one of the most severe environmental threats.
    [Show full text]
  • PDF (Book of Abstracts)
    Ninth Annual Conference of the International Society for the Study of Drug Policy Ghent (Belgium) – 20 – 22 May 2015 Venue: Het Pand With the financial support of Book of Abstracts i ISSDP conference 20-22 May 2015 Book of Abstracts Table of Contents KEYNOTE SPEAKERS ......................................................................................................................................... 5 ABDOOL, REYCHAD ................................................................................................................................................ 6 BERRIDGE, VIRGINIA .............................................................................................................................................. 7 KRAUS, LUDWIG .................................................................................................................................................... 8 MASAO, FRANK ..................................................................................................................................................... 9 MOORE, DAVID ................................................................................................................................................... 10 TOUFIQ, JALLAL ................................................................................................................................................... 11 ORAL PRESENTATIONS ................................................................................................................................... 13 AHMED, TANVIR
    [Show full text]
  • Cannabis Regulation in Europe: Country Report Denmark
    COUNTRY REPORT | February 2019 Cannabis Regulation in Europe: Country Report Denmark Maj Nygaard-Christensen and Vibeke Asmussen Frank Aarhus University ideas into movement Introduction This report examines policy and practice relating to the regulation of cannabis in Denmark. It was produced as part of a study of cannabis regulation models in Europe, funded by the European Commission and led by the Transnational Institute in Amsterdam. The broader study examines and compares experiences from European countries’ experiments with cannabis regulation, including trial proposals for legalisation or decriminalisation of cannabis use, with a particular focus on larger cities in six countries. Denmark has no legal regulation regarding recreational cannabis use, and possession, production, import/export, and buying and selling of cannabis is illegal (Dahl and Frank 2012: 13). This overview of the legal and policy framework for the regulation of cannabis first introduces the policy shifts in cannabis control in Denmark, reviews the political positions on possibilities for legalisation or decriminalisation, and the international context influencing these. It then offers an analysis of how policy and police crackdowns on the open-air cannabis market in Christiania in Copenhagen led to a dispersal and restructuring of the market, with the entry of new criminal gangs. This part of the report indicates an increasingly repressive cannabis policy in Denmark, although there are some openings in the form of a trial for medicinal cannabis commencing in 2018, and a proposed model for legalised cannabis in Copenhagen Municipality. From Tolerant to Repressive Cannabis Control Cannabis falls under the 1955 Euphoriant Substances Act, which is used for minor offences that can be punished with up to a two-year prison term, and the penal code’s §191 from 1969, which refers to the organised sale and possession of larger amounts of narcotics.
    [Show full text]
  • ©Copyright 2008 Sunil Kumar Aggarwal
    ©Copyright 2008 Sunil Kumar Aggarwal The Medical Geography of Cannabinoid Botanicals in Washington State: Access, Delivery, and Distress Sunil Kumar Aggarwal A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2008 Program Authorized to Offer Degree: Geography University of Washington Graduate School This is to certify that I have examined this copy of a doctoral dissertation by Sunil Kumar Aggarwal and have found that it is complete and satisfactory in all respects, and that any and all revisions required by the final examining committee have been made. Chair of the Supervisory Committee: ___________________________________________________ Jonathan Mayer Reading Committee: __________________________________________________ Jonathan Mayer _________________________________________________ Richard Morrill ___________________________________________________ Craig ZumBrunnen ___________________________________________________ Gregory Carter ___________________________________________________ Ethan Russo Date:__________________________ In presenting this dissertation in partial fulfillment of the requirements for the doctoral degree at the University of Washington, I agree that the Library shall make its copies freely available for inspection. I further agree that extensive copying of the dissertation is allowable only for scholarly purposes, consistent with “fair use” as prescribed in the U.S. Copyright Law. Requests for copying or reproduction of this dissertation
    [Show full text]
  • Legalization of Cannabis in India
    A Creative Connect International Publication 53 LEGALIZATION OF CANNABIS IN INDIA Written by Bhavya Bhasin 2nd year BALLB Student, Kirit P. Mehta School of Law, NMIMS ABSTRACT The underlying object of this research paper is to study and analyze why there is need to legalize cannabis in India. As it deals with the benefit that India will gain by legalizing cannabis as to how government would able to earn more revenue and would able to decrease the unemployment rate, how it would help in decreasing the crime rates in the country and it also explains the medical usage of cannabis. These aspects have been proven in research paper by comparing India with the other countries that have legalized cannabis. This research paper also deals with the current legal status of cannabis in India. ASIAN LAW & PUBLIC POLICY REVIEW ISSN 2581 6551 [VOLUME 3] DECEMBER 2018 A Creative Connect International Publication 54 INTRODUCTION Cannabis, commonly known as marijuana is a drug which is made up from Indian hemp plants like cannabis sativa and cannabis indica. The main active chemical in cannabis is Tetrahydrocannabinol(THC). Cannabis plant is used for medical purposes and recreational purposes. Cannabis is the plants that have played a vital role in the development of agriculture, which had great impact on both human beings and planet. Since many years cannabis has been used as medicinal drug, as an intoxicant and it has also been used in some religious rituals. The Hindu God Shiva is the lord of the bhang as in ‘Mahashivratri’ there is Prasad mixed with bhang and it still plays a very symbolic role in the religious practices of Hindus.
    [Show full text]
  • Legalization of Marijuana in India
    VOLUME 3 ISSUE 2 DECEMBER 2019 ISSN: 2456-9666 THE CONTROLLED LAW OF UNCOVERD HEMP: LEGALIZATION OF MARIJUANA IN INDIA -SHIVANI VYAS1 ABSTRACT: More and more states have passed laws that allow individuals to use marijuana for medical purposes. There is an ongoing, heated policy debate over whether these laws have increased marijuana use among non-patients.Medical marijuana laws generate significant debates regarding drug policy. For one thing, if marijuana is a complement to hard drugs, then these laws would increase the usage not only of marijuana but also of hard drugs. Legalization of marijuana has always been a debatable topic after the enforcement of Narcotic Drugs and Psychotropic Substances Act, 1985 illegalizing sale and possession of marijuana all over India. This paper aims at drawing a strict analysis of usage of marijuana followed with a comparative study with the rest of the world pin-pointing whether India should legalise marijuana or not. I think people need to be educated to the fact that marijuana is not a drug. Marijuana is an herb and a flower. God put it here. If he put it here and he wants it to grow, what gives the government the right to say that god is wrong? —Willie Nelson I. INTRODUCTION The idea that marijuana is a complement to hard drugs such as cocaine and heroin, or even a gateway to them, is an important but controversial justification for marijuana prohibition that has had a strong influence on India policy.Some empirical evidence suggests that marijuana consumption has increased after medical marijuana legalization.
    [Show full text]
  • Medicinal Use of Cannabis 3Rd Edition
    M E M O R A N D U M Medicinal use of Cannabis 3rd edition 2015 04/12/2015 Medicines Control & Inspection File no.2013113424/ Axel Heides Gade 1 DK-2300 Copenhagen S Frank Bøgh Madsen [email protected] Email: [email protected] Page 2 04/12/2015 Danish Medicines Agency Contents 1. Introduction ................................................................................................ 3 2. The body's own cannabinoids and receptors .............................................. 3 3. Knowledge about intoxicating and harmful effects and the prevalence of Cannabis......................................................................................................... 4 3.1. The Dutch Ministry of Health's brochure about side effects of medicinal use of Cannabis .......................................................................................... 5 4. Rules about Cannabis as a euphoriant substance ....................................... 6 4.1. List A – Cannabis ............................................................................... 6 4.2. List B – THC in pure form and other cannabinoids ............................ 7 4.3. CBD – in pure form or in hemp products ............................................ 8 5. Positive effects of medicines containing active substances from Cannabis and clinical trials ............................................................................................ 8 5.1. Other scientific evidence about Cannabis and cannabinoids ............ 10 6. Rules about medicines requiring a marketing authorisation (Sativex®)
    [Show full text]
  • Cannabis Legal Regulatory Update January
    Allen & Overy | Cannabis Legal & Regulatory Update View this email in your browser Cannabis Legal & Regulatory Update January ­ March 2019 PDF version The A&O view In the last couple of months, the WHO Expert Committee on Drug Dependence (ECDD)’s recommendations on rescheduling cannabis and its derivatives in the international drug conventions have filled the cannabis industry with hope. Removing cannabis from the strictest Schedule IV (also including heroin and cocaine) is a logical – and overdue – step given the well­established medical use of the plant. However, in particular a vote in favour of removing cannabis “extracts and tinctures” from Schedule I (as recommended by the ECDD) may open up new possibilities for the CBD industry, which often faces legal hurdles on this basis given that CBD is not a scheduled substance in itself. We may soon expect approval of the first EU­wide approved cannabis­based medicine (Epidyolex®), and the European Parliament Resolution on the use of cannabis for medical purposes, which clearly recognises its medical use and specifically calls on the EU Commission and Member States for more research and innovation in this respect, will likely make us see more of these in the future. Many EU member states and other countries have recently authorised medical cannabis (e.g. UK) or are in the process of doing so (e.g. France), in order to provide access to patients but simultaneously being aware of the extra source of state income such authorisation represents. These positive recent developments in the medical sphere could nevertheless reinforce the idea of only two categories of cannabis – licit medical use vs.
    [Show full text]